< em > LuciA-15 < /em > - a real-world prospective study of PARP inhibitors for the treatment of patients with HER-2 negative metastatic breast cancer with germline and/or somatic mutation of BRCA genes or homologous recombination repair related genes

CONCLUSION: This is the first evidence in a Latin-American population that replicates the data already published in randomised clinical trials and other scanty real-world evidence studies in this field, showing positive results in rwORR and rwPFS, and encouraging data in rwOS. Notably, there was a high proportion of patients with visceral progression even with visceral crisis and need for CT. Interestingly, there were similar rwOS results among subgroups (TNBC versus ER + ve/HER2-ve, talazoparib versus olaparib, etc).PMID:38414929 | PMC:PMC10898875 | DOI:10.3332/ecancer.2023.1634

Source: Ecancermedicalscience - February 28, 2024 Category: Cancer & Oncology Authors: Fernando E Petracci Cynthia Villarreal-Garza Facundo Arga ñaraz Gonzalo G ómez Abuin Jos é Peñaloza Marcos Ariel Flores Luciano Piazzoni Cecilia Riggi Luc ía Fabiano Luc ía González Bel én Cieplinski Sergio Rivero Ernesto Korbenfeld Pablo Mand ó Source Type: research